Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 14,432

Document Document Title
WO/2019/229250A1
The invention relates to a compound of the formula (I) as novel inhibitorof N- acylphosphatidylethanolamine phospholipase D (NAPE-PLD), and to use thereof for the prophylaxis ortreatment ofdiseases associated with NAPE-PLD. (I) wherein i...  
WO/2019/228341A1
An inhibitor containing a tricyclic derivative, a preparation method therefor and a pharmaceutical composition comprising the inhibitor, as well as a use thereof as a phosphoinositide 3 kinase (PI3K) inhibitor in the treatment of cancer ...  
WO/2019/230858A1
A compound represented in formula (I) is provided. (In the formula, ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring, etc.; R1 is a halogen, etc.;R2a and R2b are independently a hydrogen, etc.; R3 is a subst...  
WO/2019/229141A1
The invention relates to a process for producing compounds containing an oxazolopyridinone group (3) by reacting a compound comprising an ortho-aminohydroxypyridine functional group of formula (1) and a compound containing a diarylcarbon...  
WO/2019/225625A1
The present invention pertains to a compound represented by general formula (I) [the symbols in the formula are as described in the specification] or a pharmacologically acceptable salt thereof, and to a pharmaceutical composition contai...  
WO/2019/226839A1
The present disclosure concerns synthesis, anion binding features, liquid-liquid extraction of salts, and anti-corrosion character of aryl-triazole bicyclic macrocycles of Formula (I) and related compounds: Formula (I).  
WO/2019/215203A1
The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them an...  
WO/2019/214546A1
Disclosed are a compound represented by formula (I) as well as stereoisomers, tautomer or mixtures of the compound, pharmaceutically acceptable salts, eutectics, polymorphs or solvates of the compound, or stable isotope derivatives, meta...  
WO/2019/214681A1
Described herein are compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, isotopically labeled derivatives and radiolabeled derivative thereof, and pharmaceutical compositions thereof. Also provided are me...  
WO/2019/215759A1
The invention relates to a process for preparation of Midostaurin. More preferably the invention relates to process for the preparation of Midostaurin comprising reacting the staurosporine with benzoic acid in presences of condensing age...  
WO/2019/212991A1
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.  
WO/2019/210835A1
A diaryl macrocyclic compound as a protein kinase modulator. Specifically, the present invention relates to a compound in formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor and a pharmaceutical composi...  
WO/2019/212990A1
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.  
WO/2019/207602A1
The present disclosure provides crystalline forms of bictegravir, amorphous bictegravir sodium, amorphous solid dispersion of bictegravir sodium with pharmaceutically acceptable carrier and processes for the preparation thereof.  
WO/2019/208693A1
The present invention provides a compound which has an effect of inhibiting amyloid βproduction, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, se...  
WO/2019/207463A1
This invention relates to compounds of Formula (I),or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compo...  
WO/2019/209633A1
The present disclosure relates to Lorlatinib solid state forms, Lorlatinib salts and solid states thereof, processes for preparation thereof, pharmaceutical compositions and methods of use thereof.  
WO/2019/206069A1
The present invention provides a compound as represented by formula (1), or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotopic label, an isomer, or a prodrug thereof. The present invention also ...  
WO/2019/209896A1
The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as ...  
WO/2019/206237A1
The present invention provides an aminopyrimidine derivative for preventing and treating a disease associated with IDH mutation, the preparation method thereof, and the use thereof. In particular, the present invention provides a compoun...  
WO/2019/202609A1
The present invention provides a new artemisinin-dipeptidyl vinyl based compound of Formula (I) or a pharmaceutically acceptable salt thereof and a process for the preparation thereof. The present invention further also provides a pharma...  
WO/2019/204537A1
The invention provides compounds having the general formula (I): or pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R7a, R7b, X, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compos...  
WO/2019/204813A1
The disclosure provide compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore unco...  
WO/2019/201282A1
Disclosed is a macrocyclic kinase inhibitor, wherein the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is as shown in formula I. Experiments show that the new compound as shown in formula I disclosed ...  
WO/2018/187553A8
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, L and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of ...  
WO/2019/202394A1
Biomarkers for identifying Johne's disease in cattle are presented herein, as are related methods, uses, agents, and kits comprising same. Methods for treating, detecting, quarantining, and diagnosing Johne's disease in cattle are presen...  
WO/2019/204550A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.  
WO/2019/204816A1
The disclosure provides compounds of Formula ( I-A ) and ( I-B) and the pharmaceutically acceptable salts thereof. The variables, R, R2, R3, X1, X2, X3, Y1, Y, and Z are defined herein. Certain compounds of Formula ( I-A) and (I-B) act a...  
WO/2019/197502A1
The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, ester, amide or carbamate thereof, or a salt of such an ester, amide or carbamate.The invention further provides uses of the compounds of formula (I...  
WO/2019/198692A1
The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is in...  
WO/2019/199864A1
The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or in...  
WO/2019/200120A1
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.  
WO/2019/200100A1
The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, ...  
WO/2019/196891A1
The present invention discloses a group of polycyclic carbamoylpyridone derivatives, pharmaceutical compositions, and a use thereof. The structure of the polycyclic carbamoylpyridone derivatives of the present invention is represented by...  
WO/2019/197231A1
The present invention relates to new methods for producing cis-alkoxy substituted spirocyclic 1-H-pyrrolidine-2,4-dione derivatives and new intermediates or starting compounds that are used in the method according to the invention.  
WO/2019/197842A1
The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity Formula (I) wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relat...  
WO/2019/200217A1
The present disclosure relates to steroidal glucocorticoid receptor (GR) ligands and related compositions that degrade the GR and/or modulate its activity that may be utilized as pharmaceuticals for the treatment of diseases including ca...  
WO/2019/196948A1
Disclosed are a compound using an aryl ketone as a core as represented by general formula (1), a preparation method therefor and an application thereof on an OLED. A parent nucleus of the organic compound is an aryl ketone, the parent nu...  
WO/2019/195754A1
Cationic radial catenane comprising a central cationic ring and two or more radial cationic rings mechanically interlocked central cationic ring and methods for making the same are disclosed herein.  
WO/2019/195124A1
Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined...  
WO/2019/184744A1
The present invention relates to a tetrahydroisoquinoline derivative, a preparation method therefor and uses thereof, and more particularly relates to a tetrahydroisoquinoline derivative or a pharmaceutically acceptable salt, an ester, a...  
WO/2019/189555A1
Provided is a compound that can have a CDK12-inhibiting effect and that is expected to be useful as a preventive or therapeutic drug for cancer and the like. The compound or salt thereof is represented by formula (I) (where each symbol i...  
WO/2019/184955A1
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2019/191702A1
The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods f...  
WO/2019/186590A1
The present disclosure relates to compounds of Formula (I), its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active ...  
WO/2019/186343A1
The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutica...  
WO/2019/180634A1
The invention provides a novel synthesis of 3-oxo-3,4-dihydro-2H-pyrazino[2,3-b][1,4]oxazine-6-carbaldeh yde.  
WO/2019/180185A1
The invention provides new heterocyclic compounds having the general formula (Ic) wherein A, L, X, m, n and R20 to R23 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of...  
WO/2019/178677A1
The present disclosure relates to the targeted delivery of defined active agents and/or immunomodulatory agents to lymph nodes or lipoid cells in a lymphatic tissue. More particularly, the invention provides methods for targeted delivery...  
WO/2019/180188A1
The present invention relates to aminopropoxyphenyl and benzyl 1-oxa-4,9- diazaspiroundecanederivatives having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium ...  

Matches 201 - 250 out of 14,432